[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,690,512
  • Shares Outstanding, K 199,782
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,611 M
  • EBITDA $ 1,704 M
  • 60-Month Beta 0.79
  • Price/Sales 3.80
  • Price/Cash Flow 15.82
  • Price/Book 3.47

Options Overview Details

View History
  • Implied Volatility 34.31% (-1.68%)
  • Historical Volatility 27.51%
  • IV Percentile 33%
  • IV Rank 23.61%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 5) 4.78 (4.85%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 453
  • Volume Avg (30-Day) 560
  • Put/Call OI Ratio 1.17
  • Today's Open Interest 15,931
  • Open Int (30-Day) 13,996
  • Expected Range 93.78 to 103.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.61
  • Number of Estimates 7
  • High Estimate $1.73
  • Low Estimate $1.38
  • Prior Year $1.31
  • Growth Rate Est. (year over year) +22.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.79 +6.22%
on 04/28/26
102.86 -4.18%
on 04/29/26
+2.67 (+2.78%)
since 04/08/26
3-Month
89.25 +10.43%
on 03/24/26
109.48 -9.97%
on 02/09/26
-9.83 (-9.07%)
since 02/06/26
52-Week
58.94 +67.22%
on 05/09/25
112.29 -12.23%
on 01/07/26
+38.83 (+65.01%)
since 05/08/25

Most Recent Stories

More News
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs)...

INCY : 98.56 (+0.81%)
2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore

2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore

INSP : 44.26 (-2.87%)
INCY : 98.56 (+0.81%)
RJF : 154.33 (+0.52%)
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Corporation (Nasdaq:INCY) announced today that it granted equity inducement awards to Suketu (Suky) Upadhyay, the Company’s new Executive Vice President and Chief Financial Officer, pursuant to...

INCY : 98.56 (+0.81%)
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions

Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions

INCY : 98.56 (+0.81%)
Incyte Announces FDA Approval of Jakafi XRâ„¢ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi ® (ruxolitinib) ...

INCY : 98.56 (+0.81%)
Incyte to Present at Upcoming Investor Conferences

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: BofA Securities 2026 Health Care Conference on Wednesday,...

INCY : 98.56 (+0.81%)
INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance

INCY Q1 Deep Dive: Pipeline Advances Offset Cautious Full-Year Guidance

INCY : 98.56 (+0.81%)
Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations

Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations

INCY : 98.56 (+0.81%)
Incyte: Q1 Earnings Snapshot

Incyte: Q1 Earnings Snapshot

INCY : 98.56 (+0.81%)
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

Incyte (Nasdaq:INCY) announces the appointment of Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer (CFO) effective May 4, 2026. In his new role, Mr. Upadhyay will serve as...

INCY : 98.56 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 102.20
2nd Resistance Point 101.03
1st Resistance Point 99.80
Last Price 98.56
1st Support Level 97.40
2nd Support Level 96.23
3rd Support Level 95.00

See More

52-Week High 112.29
Last Price 98.56
Fibonacci 61.8% 91.91
Fibonacci 50% 85.61
Fibonacci 38.2% 79.32
52-Week Low 58.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.